JP2008511670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008511670A5 JP2008511670A5 JP2007530356A JP2007530356A JP2008511670A5 JP 2008511670 A5 JP2008511670 A5 JP 2008511670A5 JP 2007530356 A JP2007530356 A JP 2007530356A JP 2007530356 A JP2007530356 A JP 2007530356A JP 2008511670 A5 JP2008511670 A5 JP 2008511670A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound
- ring
- heteroatoms
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005842 heteroatom Chemical group 0.000 claims description 46
- 229920006395 saturated elastomer Polymers 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 125000002950 monocyclic group Chemical group 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- 125000001931 aliphatic group Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 239000011593 sulfur Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 76
- 208000002193 Pain Diseases 0.000 claims 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- -1 tetrahydropyranyl compound Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 208000008035 Back Pain Diseases 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000005298 acute pain Diseases 0.000 claims 4
- 125000001118 alkylidene group Chemical group 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 4
- 206010019233 Headaches Diseases 0.000 claims 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 3
- 208000004404 Intractable Pain Diseases 0.000 claims 3
- 206010028836 Neck pain Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000002981 neuropathic effect Effects 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000000003 Breakthrough pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000006561 Cluster Headache Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010016059 Facial pain Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims 1
- 206010061533 Myotonia Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 206010040037 Sensory neuropathy hereditary Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims 1
- 201000006847 hereditary sensory neuropathy Diseases 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000001288 lysyl group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 210000003371 toe Anatomy 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000026533 urinary bladder disease Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 2
- 0 CC(CN(C1)c2nc(-c3ccccc3O)nc3c2cccc3)N1C(C(*)*)=O Chemical compound CC(CN(C1)c2nc(-c3ccccc3O)nc3c2cccc3)N1C(C(*)*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60724504P | 2004-09-02 | 2004-09-02 | |
| US60703304P | 2004-09-02 | 2004-09-02 | |
| US60715004P | 2004-09-02 | 2004-09-02 | |
| US60703604P | 2004-09-02 | 2004-09-02 | |
| US60703704P | 2004-09-02 | 2004-09-02 | |
| US60/607,036 | 2004-09-02 | ||
| US60/607,245 | 2004-09-02 | ||
| US60/607,037 | 2004-09-02 | ||
| US60/607,033 | 2004-09-02 | ||
| US60/607,150 | 2004-09-02 | ||
| PCT/US2005/031146 WO2006028904A1 (en) | 2004-09-02 | 2005-08-31 | Quinazolines useful as modulators of ion channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008511670A JP2008511670A (ja) | 2008-04-17 |
| JP2008511670A5 true JP2008511670A5 (https=) | 2011-12-22 |
| JP5014994B2 JP5014994B2 (ja) | 2012-08-29 |
Family
ID=35517001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007530356A Expired - Fee Related JP5014994B2 (ja) | 2004-09-02 | 2005-08-31 | イオンチャネルのモジュレーターとして有用なキナゾリン |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1784393B1 (https=) |
| JP (1) | JP5014994B2 (https=) |
| KR (1) | KR20070057914A (https=) |
| CN (1) | CN101068794B (https=) |
| AT (1) | ATE435214T1 (https=) |
| AU (1) | AU2005282761B2 (https=) |
| BR (1) | BRPI0514893A (https=) |
| CA (1) | CA2578739A1 (https=) |
| DE (1) | DE602005015231D1 (https=) |
| ES (1) | ES2327945T4 (https=) |
| IL (1) | IL181700A0 (https=) |
| MA (1) | MA28909B1 (https=) |
| MX (1) | MX2007002582A (https=) |
| NO (1) | NO20071742L (https=) |
| NZ (1) | NZ589252A (https=) |
| RU (1) | RU2440991C2 (https=) |
| WO (1) | WO2006028904A1 (https=) |
| ZA (1) | ZA200702375B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2413731C2 (ru) | 2004-04-09 | 2011-03-10 | Чугаи Сейяку Кабусики Кайся | Новые растворимые в воде пролекарства |
| US7928107B2 (en) | 2004-09-02 | 2011-04-19 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
| TW200744603A (en) | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| CA2626330A1 (en) * | 2005-10-19 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-solube prodrug |
| ES2377988T3 (es) | 2005-11-14 | 2012-04-03 | Vertex Pharmaceuticals, Inc. | Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje |
| EP1968968A1 (en) * | 2005-12-21 | 2008-09-17 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
| EP2043654A2 (en) * | 2006-06-12 | 2009-04-08 | Vertex Pharmaceuticals, Inc. | Thienopyrimidines useful as modulators of ion channels |
| CA2707449A1 (en) | 2006-12-01 | 2009-06-12 | President And Fellows Of Harvard College | Compounds and methods for enzyme-mediated tumor imaging and therapy |
| WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| US20090209536A1 (en) * | 2007-06-17 | 2009-08-20 | Kalypsys, Inc. | Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| EP2625169B1 (en) | 2010-10-05 | 2015-03-25 | Purdue Pharma L.P. | Quinazoline compounds as sodium channel blockers |
| US20140080810A1 (en) | 2010-11-15 | 2014-03-20 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture |
| WO2012104866A1 (en) | 2011-01-31 | 2012-08-09 | Council Of Scientific & Industrial Research | Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl- aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion |
| ES2602140T3 (es) | 2011-06-27 | 2017-02-17 | Newron Pharmaceuticals S.P.A. | Derivados de arilalquilaminocarboxamida fluorados |
| EP3438096B1 (en) * | 2016-04-01 | 2020-12-02 | Impact Therapeutics, Inc | Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione |
| CA3071024A1 (en) | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN111201245B (zh) | 2017-09-01 | 2024-04-05 | 戴纳立制药公司 | 化合物、组合物和方法 |
| WO2019183589A1 (en) * | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| CA3106470A1 (en) * | 2018-07-17 | 2020-01-23 | Nippon Chemiphar Co., Ltd. | T-type calcium channel blocker |
| SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
| EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US12479830B2 (en) * | 2019-10-10 | 2025-11-25 | Esteve Pharmaceuticals, S.A. | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain |
| CA3164134A1 (en) | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| CN119757730A (zh) * | 2024-12-24 | 2025-04-04 | 浙江省海洋水产研究所 | 一种河豚毒素的胶体金检测卡 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH083144A (ja) * | 1994-06-21 | 1996-01-09 | Chugai Pharmaceut Co Ltd | キナゾリン及びキノリン誘導体 |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| EP1230225A2 (en) * | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
| SE0004055D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| SE0004054D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| DE60236322D1 (de) * | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| ZA200601859B (en) * | 2003-08-05 | 2008-03-26 | Vertex Pharma | Condensed pyrimidine compounds as inhibitors of voltagegated ion channels |
| WO2006127329A1 (en) * | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Quinoline derivatives useful as modulators of ion channels |
-
2005
- 2005-08-31 BR BRPI0514893-6A patent/BRPI0514893A/pt not_active IP Right Cessation
- 2005-08-31 WO PCT/US2005/031146 patent/WO2006028904A1/en not_active Ceased
- 2005-08-31 MX MX2007002582A patent/MX2007002582A/es unknown
- 2005-08-31 AT AT05807734T patent/ATE435214T1/de active
- 2005-08-31 ES ES05807734T patent/ES2327945T4/es not_active Expired - Lifetime
- 2005-08-31 RU RU2007111897/04A patent/RU2440991C2/ru not_active IP Right Cessation
- 2005-08-31 CA CA002578739A patent/CA2578739A1/en not_active Abandoned
- 2005-08-31 ZA ZA200702375A patent/ZA200702375B/xx unknown
- 2005-08-31 AU AU2005282761A patent/AU2005282761B2/en not_active Ceased
- 2005-08-31 NZ NZ589252A patent/NZ589252A/en not_active IP Right Cessation
- 2005-08-31 JP JP2007530356A patent/JP5014994B2/ja not_active Expired - Fee Related
- 2005-08-31 KR KR1020077007601A patent/KR20070057914A/ko not_active Ceased
- 2005-08-31 EP EP05807734A patent/EP1784393B1/en not_active Expired - Lifetime
- 2005-08-31 CN CN2005800374969A patent/CN101068794B/zh not_active Expired - Fee Related
- 2005-08-31 DE DE602005015231T patent/DE602005015231D1/de not_active Expired - Lifetime
-
2007
- 2007-03-02 MA MA29735A patent/MA28909B1/fr unknown
- 2007-03-04 IL IL181700A patent/IL181700A0/en unknown
- 2007-04-02 NO NO20071742A patent/NO20071742L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008511670A5 (https=) | ||
| DE69329574T2 (de) | Pharmazeutisch wirksame bicyclisch heterocyclische amine | |
| WO2022271658A1 (en) | Tricyclic kras inhibitors | |
| RU2334744C2 (ru) | Макроциклические соединения, которые могут быть использованы в качестве фармацевтических препаратов | |
| DE60217118T2 (de) | 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer | |
| WO2022266069A1 (en) | Tricyclic kras g12d inhibitors | |
| JP2011500598A5 (https=) | ||
| RU2007111897A (ru) | Хиназолины, полезные в качестве модуляторов ионных каналов перекрестные ссылки на родственные заявки | |
| CA3172203A1 (en) | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds | |
| EP2773623B1 (en) | 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof | |
| EP2032585B1 (de) | Substituierte pteridine als therapeutika | |
| KR20200083553A (ko) | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 | |
| TR201808380T4 (tr) | Napdh Oksidaz enzimleri olarak Pirazolo Piridin Türevleri. | |
| JP2010539244A5 (https=) | ||
| JP2012509332A5 (https=) | ||
| WO2021178339A1 (en) | Heterobifunctional molecules as tead inhibitors | |
| EP3705480B1 (en) | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof | |
| KR970003440A (ko) | 삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘 | |
| JP2019512459A (ja) | ７員環化合物、その調製方法、その医薬組成物、およびその使用 | |
| EP2661436B1 (en) | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| RU2018103753A (ru) | Ингибиторы гистондеацетилазы | |
| DE69817810T2 (de) | Cyanoguanidine als zellproliferation inhibitoren | |
| EP3590516A1 (en) | Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound | |
| CN110088108B (zh) | 取代的吡唑并氮杂䓬-4-酮类及其作为磷酸二酯酶抑制剂的用途 | |
| EP1828189A1 (de) | Substituierte pteridine zur behandlung von entz]ndlichen erkrankungen |